388630-74-8 Usage
Uses
Used in Pharmaceutical and Agrochemical Industries:
Cyclohexanecarboxamide, 3-amino-N,N-dimethylis used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals, contributing to the development of new drugs and pesticides.
Used as a Stabilizer and Corrosion Inhibitor in Industrial Applications:
In various industries, Cyclohexanecarboxamide, 3-amino-N,N-dimethylis utilized as a stabilizer to prevent the degradation of materials and as a corrosion inhibitor to protect metal surfaces from corrosion.
Used in the Production of Biodegradable Polymers:
Cyclohexanecarboxamide, 3-amino-N,N-dimethylplays a significant role in the production of biodegradable polymers, which are environmentally friendly alternatives to traditional plastics.
Used as a Building Block in Organic Chemistry:
As an important building block in organic chemistry, Cyclohexanecarboxamide, 3-amino-N,N-dimethylis employed in the synthesis of various organic compounds, facilitating the development of new chemical entities.
Used in Therapeutic Applications:
Cyclohexanecarboxamide, 3-amino-N,N-dimethylhas been studied for its potential use as a therapeutic agent in the treatment of various diseases, offering new avenues for medical research and drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 388630-74-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,8,8,6,3 and 0 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 388630-74:
(8*3)+(7*8)+(6*8)+(5*6)+(4*3)+(3*0)+(2*7)+(1*4)=188
188 % 10 = 8
So 388630-74-8 is a valid CAS Registry Number.
388630-74-8Relevant academic research and scientific papers
Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides
Pryde, David C.,Maw, Graham N.,Planken, Simon,Platts, Michelle Y.,Sanderson, Vivienne,Corless, Martin,Stobie, Alan,Barber, Christopher G.,Russell, Rachel,Foster, Laura,Barker, Laura,Wayman, Christopher,Van Der Graaf, Piet,Stacey, Peter,Morren, Debbie,Kohl, Christopher,Beaumont, Kevin,Coggon, Sara,Tute, Michael
, p. 4409 - 4424 (2007/10/03)
Female sexual arousal disorder (FSAD) is a highly prevalent sexual disorder affecting up to 40% of women. We describe herein our efforts to identify a selective neutral endopeptidase (NEP) inhibitor as a potential treatment for FSAD. The rationale for this approach, together with a description of the medicinal chemistry strategy, lead compounds, and SAR investigations are detailed. In particular, the strategy of starting with the clinically precedented selective NEP inhibitor, Candoxatrilat, and targeting low molecular weight and relatively polar mono-carboxylic acids is described. This led ultimately to the prototype development candidate R-13, for which detailed pharmacology and pharmacokinetic parameters are presented.
